Free Trial

Compare Stocks

Comparative Price Performance Over Time

Compare Stocks - Price & Volume

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Exscientia plc stock logo
EXAI
Exscientia
$4.86
-5.3%
$5.09
$3.80
$7.91
$587.51M0.84633,334 shs446,539 shs
Alphabet Inc. stock logo
GOOG
Alphabet
$172.69
-2.0%
$163.56
$123.93
$193.31
$2.13T1.0419.71 million shs32.74 million shs
NVIDIA Co. stock logo
NVDA
NVIDIA
$132.76
-4.7%
$124.95
$39.23
$144.42
$3.26T1.67410.00 million shs269.25 million shs
Recursion Pharmaceuticals, Inc. stock logo
RXRX
Recursion Pharmaceuticals
$6.32
-5.4%
$6.68
$4.97
$15.74
$1.78B0.85.68 million shs4.38 million shs
Banco Santander, S.A. stock logo
SAN
Banco Santander
$4.86
-0.4%
$4.95
$3.60
$5.27
$76.83B1.142.72 million shs3.23 million shs
Schrödinger, Inc. stock logo
SDGR
Schrödinger
$17.60
+0.1%
$19.03
$16.67
$38.00
$1.28B1.5741,774 shs824,864 shs
Sanofi stock logo
SNY
Sanofi
$52.88
-1.1%
$56.02
$45.00
$58.97
$134.20B0.62.04 million shs1.40 million shs
Sanofi stock logo
SNYNF
Sanofi
$105.00
+0.1%
$110.89
$88.34
$119.65
N/AN/A16,207 shs555 shs
(Almost)  Everything You Need To Know About The EV Market Cover

Click the link below and we'll send you MarketBeat's guide to investing in electric vehicle technologies (EV) and which EV stocks show the most promise.

Get This Free Report

Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Exscientia plc stock logo
EXAI
Exscientia
+0.39%+5.34%+5.12%+11.52%-5.00%
Alphabet Inc. stock logo
GOOG
Alphabet
+2.92%+7.09%+5.35%+2.14%+40.57%
NVIDIA Co. stock logo
NVDA
NVIDIA
-1.36%-0.16%+14.74%+27.58%+241.67%
Recursion Pharmaceuticals, Inc. stock logo
RXRX
Recursion Pharmaceuticals
-0.89%+5.53%+1.37%-8.99%+26.52%
Banco Santander, S.A. stock logo
SAN
Banco Santander
+0.21%-1.51%-4.22%+6.67%+34.25%
Schrödinger, Inc. stock logo
SDGR
Schrödinger
-6.19%-2.98%-5.23%-22.21%-18.99%
Sanofi stock logo
SNY
Sanofi
-0.71%+1.06%-7.25%+3.46%+18.12%
Sanofi stock logo
SNYNF
Sanofi
0.00%-3.10%-7.59%+4.59%+17.33%

MarketRank™

CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Exscientia plc stock logo
EXAI
Exscientia
2.0979 of 5 stars
3.02.00.00.02.71.70.6
Alphabet Inc. stock logo
GOOG
Alphabet
4.6959 of 5 stars
3.43.01.72.92.01.72.5
NVIDIA Co. stock logo
NVDA
NVIDIA
4.6221 of 5 stars
2.53.01.73.01.92.53.1
Recursion Pharmaceuticals, Inc. stock logo
RXRX
Recursion Pharmaceuticals
2.8722 of 5 stars
3.22.00.00.03.13.30.6
Banco Santander, S.A. stock logo
SAN
Banco Santander
4.189 of 5 stars
0.03.02.52.83.00.04.4
Schrödinger, Inc. stock logo
SDGR
Schrödinger
2.2386 of 5 stars
3.40.00.00.03.12.50.6
Sanofi stock logo
SNY
Sanofi
2.3161 of 5 stars
1.44.01.70.02.60.02.5
Sanofi stock logo
SNYNF
Sanofi
1.7142 of 5 stars
0.02.01.74.02.10.01.3

Analyst Ratings

CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Exscientia plc stock logo
EXAI
Exscientia
2.00
Hold$7.0044.03% Upside
Alphabet Inc. stock logo
GOOG
Alphabet
2.85
Moderate Buy$200.5616.14% Upside
NVIDIA Co. stock logo
NVDA
NVIDIA
2.95
Moderate Buy$143.077.77% Upside
Recursion Pharmaceuticals, Inc. stock logo
RXRX
Recursion Pharmaceuticals
2.33
Hold$9.4048.73% Upside
Banco Santander, S.A. stock logo
SAN
Banco Santander
3.50
Strong BuyN/AN/A
Schrödinger, Inc. stock logo
SDGR
Schrödinger
2.82
Moderate Buy$32.6085.28% Upside
Sanofi stock logo
SNY
Sanofi
2.75
Moderate Buy$57.508.74% Upside
Sanofi stock logo
SNYNF
Sanofi
N/AN/AN/AN/A

Current Analyst Ratings

Latest SDGR, GOOG, NVDA, SAN, SNY, SNYNF, RXRX, and EXAI Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
10/30/2024
Alphabet Inc. stock logo
GOOG
Alphabet
Oppenheimer
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetOutperform ➝ Outperform$185.00 ➝ $215.00
10/30/2024
Alphabet Inc. stock logo
GOOG
Alphabet
JPMorgan Chase & Co.
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetOverweight ➝ Overweight$208.00 ➝ $212.00
10/30/2024
Alphabet Inc. stock logo
GOOG
Alphabet
Barclays
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetOverweight ➝ Overweight$200.00 ➝ $220.00
10/30/2024
Alphabet Inc. stock logo
GOOG
Alphabet
Citigroup
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$212.00 ➝ $216.00
10/30/2024
Alphabet Inc. stock logo
GOOG
Alphabet
Wells Fargo & Company
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetEqual Weight ➝ Equal Weight$182.00 ➝ $187.00
10/30/2024
Alphabet Inc. stock logo
GOOG
Alphabet
Canaccord Genuity Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$220.00 ➝ $225.00
10/30/2024
Alphabet Inc. stock logo
GOOG
Alphabet
UBS Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetNeutral ➝ Neutral$187.00 ➝ $192.00
10/30/2024
Alphabet Inc. stock logo
GOOG
Alphabet
Pivotal Research
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$215.00 ➝ $225.00
10/30/2024
Alphabet Inc. stock logo
GOOG
Alphabet
Jefferies Financial Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$220.00 ➝ $235.00
10/29/2024
Alphabet Inc. stock logo
GOOG
Alphabet
Seaport Res Ptn
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeHold ➝ Strong-Buy
10/18/2024
NVIDIA Co. stock logo
NVDA
NVIDIA
Bank of America
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$165.00 ➝ $190.00
(Data available from 10/31/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Sales & Book Value

CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Exscientia plc stock logo
EXAI
Exscientia
$21.02M27.95N/AN/A$3.66 per share1.33
Alphabet Inc. stock logo
GOOG
Alphabet
$328.28B6.50$7.14 per share24.19$22.79 per share7.58
NVIDIA Co. stock logo
NVDA
NVIDIA
$96.31B33.81$1.16 per share114.08$1.72 per share77.19
Recursion Pharmaceuticals, Inc. stock logo
RXRX
Recursion Pharmaceuticals
$48.62M36.54N/AN/A$1.98 per share3.19
Banco Santander, S.A. stock logo
SAN
Banco Santander
$62.45B1.23$0.94 per share5.16$6.97 per share0.70
Schrödinger, Inc. stock logo
SDGR
Schrödinger
$200.63M6.38$0.64 per share27.56$7.60 per share2.32
Sanofi stock logo
SNY
Sanofi
$48.86B2.75$6.22 per share8.50$31.81 per share1.66
Sanofi stock logo
SNYNF
Sanofi
N/AN/AN/AN/AN/AN/A

Profitability & Earnings

CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Exscientia plc stock logo
EXAI
Exscientia
-$181.56M-$1.30N/AN/AN/A-620.99%-37.56%-26.19%11/14/2024 (Estimated)
Alphabet Inc. stock logo
GOOG
Alphabet
$73.80B$6.5224.7819.961.2726.70%30.49%21.63%2/4/2025 (Estimated)
NVIDIA Co. stock logo
NVDA
NVIDIA
$29.76B$2.1362.2737.611.5055.04%113.50%73.83%11/20/2024 (Confirmed)
Recursion Pharmaceuticals, Inc. stock logo
RXRX
Recursion Pharmaceuticals
-$328.07M-$1.62N/AN/AN/A-755.37%-79.47%-57.28%11/6/2024 (Confirmed)
Banco Santander, S.A. stock logo
SAN
Banco Santander
$11.99B$0.776.315.460.4315.35%11.42%0.66%1/29/2025 (Estimated)
Schrödinger, Inc. stock logo
SDGR
Schrödinger
$40.72M-$1.88N/AN/AN/A-100.42%-38.38%-26.66%11/6/2024 (Estimated)
Sanofi stock logo
SNY
Sanofi
$5.84B$1.9626.9810.991.559.96%20.59%11.84%2/6/2025 (Estimated)
Sanofi stock logo
SNYNF
Sanofi
N/A$3.0834.04N/AN/AN/AN/AN/A

Latest SDGR, GOOG, NVDA, SAN, SNY, SNYNF, RXRX, and EXAI Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
11/20/2024N/A
NVIDIA Co. stock logo
NVDA
NVIDIA
$0.69N/A-$0.69N/AN/AN/A
11/6/2024N/A
Recursion Pharmaceuticals, Inc. stock logo
RXRX
Recursion Pharmaceuticals
-$0.33N/A+$0.33N/AN/AN/A
10/29/2024Q3 2024
Alphabet Inc. stock logo
GOOG
Alphabet
$1.83$2.12+$0.29$2.12$86.39 billion$88.27 billion      
10/25/2024Q3 2024
Sanofi stock logo
SNY
Sanofi
$0.22$1.57+$1.35$1.91$16.59 billion$13.44 billion    
8/28/2024Q2 2025
NVIDIA Co. stock logo
NVDA
NVIDIA
$0.64$0.68+$0.04$0.63$28.74 billion$30.04 billion      
8/15/2024N/A
Exscientia plc stock logo
EXAI
Exscientia
-$0.31-$0.36-$0.05-$0.36N/A$5.60 million
8/8/2024Q2 2024
Recursion Pharmaceuticals, Inc. stock logo
RXRX
Recursion Pharmaceuticals
-$0.35-$0.40-$0.05-$0.40$11.96 million$14.42 million      
7/31/2024Q2 2024
Schrödinger, Inc. stock logo
SDGR
Schrödinger
-$0.85-$0.74+$0.11-$0.74$40.19 million$47.33 million

Dividends

CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Exscientia plc stock logo
EXAI
Exscientia
N/AN/AN/AN/AN/A
Alphabet Inc. stock logo
GOOG
Alphabet
$0.800.46%N/A12.27%N/A
NVIDIA Co. stock logo
NVDA
NVIDIA
$0.040.03%N/A1.88%N/A
Recursion Pharmaceuticals, Inc. stock logo
RXRX
Recursion Pharmaceuticals
N/AN/AN/AN/AN/A
Banco Santander, S.A. stock logo
SAN
Banco Santander
$0.163.30%N/A20.78%N/A
Schrödinger, Inc. stock logo
SDGR
Schrödinger
N/AN/AN/AN/AN/A
Sanofi stock logo
SNY
Sanofi
$1.472.78%+3.79%75.00%N/A
Sanofi stock logo
SNYNF
Sanofi
$2.802.67%N/A90.78%N/A

Latest SDGR, GOOG, NVDA, SAN, SNY, SNYNF, RXRX, and EXAI Dividends

AnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
10/29/2024
Alphabet Inc. stock logo
GOOG
Alphabet
Quarterly$0.200.45%12/9/202412/9/202412/16/2024
9/26/2024
Banco Santander, S.A. stock logo
SAN
Banco Santander
Semi-Annual$0.083%10/31/202410/31/202411/6/2024
8/28/2024
NVIDIA Co. stock logo
NVDA
NVIDIA
quarterly$0.010.03%9/12/20249/12/202410/3/2024
(Data available from 1/1/2013 forward)

Debt

CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Exscientia plc stock logo
EXAI
Exscientia
0.06
5.93
5.93
Alphabet Inc. stock logo
GOOG
Alphabet
0.04
2.08
2.08
NVIDIA Co. stock logo
NVDA
NVIDIA
0.15
4.27
3.79
Recursion Pharmaceuticals, Inc. stock logo
RXRX
Recursion Pharmaceuticals
0.04
6.07
6.07
Banco Santander, S.A. stock logo
SAN
Banco Santander
N/A
0.23
0.23
Schrödinger, Inc. stock logo
SDGR
Schrödinger
N/A
4.50
4.50
Sanofi stock logo
SNY
Sanofi
0.17
1.00
0.65
Sanofi stock logo
SNYNF
Sanofi
N/AN/AN/A

Ownership

Institutional Ownership

CompanyInstitutional Ownership
Exscientia plc stock logo
EXAI
Exscientia
41.58%
Alphabet Inc. stock logo
GOOG
Alphabet
27.26%
NVIDIA Co. stock logo
NVDA
NVIDIA
65.27%
Recursion Pharmaceuticals, Inc. stock logo
RXRX
Recursion Pharmaceuticals
89.06%
Banco Santander, S.A. stock logo
SAN
Banco Santander
9.19%
Schrödinger, Inc. stock logo
SDGR
Schrödinger
79.05%
Sanofi stock logo
SNY
Sanofi
10.04%
Sanofi stock logo
SNYNF
Sanofi
30.06%

Insider Ownership

CompanyInsider Ownership
Exscientia plc stock logo
EXAI
Exscientia
16.40%
Alphabet Inc. stock logo
GOOG
Alphabet
12.99%
NVIDIA Co. stock logo
NVDA
NVIDIA
4.23%
Recursion Pharmaceuticals, Inc. stock logo
RXRX
Recursion Pharmaceuticals
15.75%
Banco Santander, S.A. stock logo
SAN
Banco Santander
9.48%
Schrödinger, Inc. stock logo
SDGR
Schrödinger
8.60%
Sanofi stock logo
SNY
Sanofi
1.00%
Sanofi stock logo
SNYNF
Sanofi
N/A

Miscellaneous

CompanyEmployeesShares OutstandingFree FloatOptionable
Exscientia plc stock logo
EXAI
Exscientia
280120.89 million101.06 millionOptionable
Alphabet Inc. stock logo
GOOG
Alphabet
190,20012.36 billion10.71 billionOptionable
NVIDIA Co. stock logo
NVDA
NVIDIA
29,60024.53 billion23.49 billionOptionable
Recursion Pharmaceuticals, Inc. stock logo
RXRX
Recursion Pharmaceuticals
400281.11 million236.83 millionOptionable
Banco Santander, S.A. stock logo
SAN
Banco Santander
212,76415.83 billion14.33 billionOptionable
Schrödinger, Inc. stock logo
SDGR
Schrödinger
86772.80 million66.54 millionOptionable
Sanofi stock logo
SNY
Sanofi
86,0882.54 billion2.51 billionOptionable
Sanofi stock logo
SNYNF
Sanofi
91,600N/AN/ANot Optionable

SDGR, GOOG, NVDA, SAN, SNY, SNYNF, RXRX, and EXAI Headlines

Recent News About These Companies

DZ BANK AG Sticks to Its Hold Rating for Sanofi (SNYNF)
Sanofi (SNYNF) Receives a Sell from Deutsche Bank
Sanofi Q3 Profit Rises - Quick Facts
Sanofi’s Strategic Moves and Financial Prospects Drive Buy Rating
Sanofi Enters Exclusive Negotiations To Sell 50% Stake In Opella To CD&R
Berenberg Bank Remains a Buy on Sanofi (SNYNF)
Deutsche Bank Sticks to Their Sell Rating for Sanofi (SNYNF)
Sanofi pauses enrolment in ex-US tolebrutinib trials
Sanofi drops BTK drug tolebrutinib in myasthenia gravis

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All Headlines

Company Descriptions

Exscientia logo

Exscientia

NASDAQ:EXAI
Exscientia plc, an artificial intelligence (AI) driven Pharma-tech company, engages in design and develop differentiated medicines for diseases with high unmet patient needs. The company's lead product candidate GTAEXS617, a CDK7 inhibitor, which is currently in a Phase 1/2 trial to manage the potential toxicities associated with CDK7 as well as optimizing pharmacokinetics for maximizing on-target efficacy. It is also involved in the development of EXS4318, a PKC-theta inhibitor, under Phase 1 clinical trial for inflammation and immunology indications; EXS74539, a LSD1 inhibitor, under preclinical studies for SCLC, AML, and potential additional indications; EXS73565, a MALT1 inhibitor, under preclinical studies for multiple hematology indications; and DSP-0038, currently in Phase 1 studies. The company has collaboration agreements with Merck KGaA, Bristol Myers Squibb, Sanofi, Bill & Melinda Gates Foundation, Charité Universitätsmedizin Berlin, Rallybio, and GT Apeiron Therapeutics. Exscientia plc was founded in 2012 and is headquartered in Oxford, the United Kingdom.
Alphabet logo

Alphabet

NASDAQ:GOOG
Alphabet Inc. offers various products and platforms in the United States, Europe, the Middle East, Africa, the Asia-Pacific, Canada, and Latin America. It operates through Google Services, Google Cloud, and Other Bets segments. The Google Services segment provides products and services, including ads, Android, Chrome, devices, Gmail, Google Drive, Google Maps, Google Photos, Google Play, Search, and YouTube. It is also involved in the sale of apps and in-app purchases and digital content in the Google Play and YouTube; and devices, as well as in the provision of YouTube consumer subscription services. The Google Cloud segment offers infrastructure, cybersecurity, databases, analytics, AI, and other services; Google Workspace that include cloud-based communication and collaboration tools for enterprises, such as Gmail, Docs, Drive, Calendar, and Meet; and other services for enterprise customers. The Other Bets segment sells healthcare-related and internet services. The company was incorporated in 1998 and is headquartered in Mountain View, California.
NVIDIA logo

NVIDIA

NASDAQ:NVDA
NVIDIA Corporation provides graphics and compute and networking solutions in the United States, Taiwan, China, Hong Kong, and internationally. The Graphics segment offers GeForce GPUs for gaming and PCs, the GeForce NOW game streaming service and related infrastructure, and solutions for gaming platforms; Quadro/NVIDIA RTX GPUs for enterprise workstation graphics; virtual GPU or vGPU software for cloud-based visual and virtual computing; automotive platforms for infotainment systems; and Omniverse software for building and operating metaverse and 3D internet applications. The Compute & Networking segment comprises Data Center computing platforms and end-to-end networking platforms, including Quantum for InfiniBand and Spectrum for Ethernet; NVIDIA DRIVE automated-driving platform and automotive development agreements; Jetson robotics and other embedded platforms; NVIDIA AI Enterprise and other software; and DGX Cloud software and services. The company's products are used in gaming, professional visualization, data center, and automotive markets. It sells its products to original equipment manufacturers, original device manufacturers, system integrators and distributors, independent software vendors, cloud service providers, consumer internet companies, add-in board manufacturers, distributors, automotive manufacturers and tier-1 automotive suppliers, and other ecosystem participants. NVIDIA Corporation was incorporated in 1993 and is headquartered in Santa Clara, California.
Recursion Pharmaceuticals logo

Recursion Pharmaceuticals

NASDAQ:RXRX
Recursion Pharmaceuticals, Inc. operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase 2 clinical trial to treat cerebral cavernous malformation; REC-2282, which is in Phase 2/3 clinical trial for the treatment of neurofibromatosis type 2; REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-3964, which is in Phase 1 clinical trial to treat Clostridioides difficile infection; and REC-4881, which is in Phase 2 clinical trial to treat AXIN1 or APC mutant cancers. Its preclinical stage product includes RBM39 to treat HR-proficient ovarian cancer. The company has collaboration and agreement with Bayer AG; the University of Utah Research Foundation; Ohio State Innovation Foundation; Roche & Genentech; and Takeda Pharmaceutical Company Limited. Recursion Pharmaceuticals, Inc. was incorporated in 2013 and is headquartered in Salt Lake City, Utah.
Banco Santander logo

Banco Santander

NYSE:SAN
Banco Santander, S.A. provides various financial services worldwide. The company operates through Retail Banking, Santander Corporate & Investment Banking, Wealth Management & Insurance, and PagoNxt segments. It offers demand and time deposits, mutual funds, and current and savings accounts; mortgages, consumer finance, loans, and various financing solutions; and project finance, debt capital markets, global transaction banking, and corporate finance services. The company also provides asset management and private banking services; and insurance products. In addition, it offers corporate and investment banking services; and digital payment solutions. Further, it offers online banking and financial services to retail, business, institutional, corporate, private banking and university customers and clients. The company was formerly known as Banco Santander Central Hispano SA and changed its name to Banco Santander, S.A. in February 2007. Banco Santander, S.A. was founded in 1856 and is headquartered in Madrid, Spain.
Schrödinger logo

Schrödinger

NASDAQ:SDGR
Schrödinger, Inc., together with its subsidiaries, develops physics-based computational platform that enables discovery of novel molecules for drug development and materials applications. The company operates in two segments, Software and Drug Discovery. The Software segment is focused on licensing its software to transform molecular discovery for life sciences and materials science industries. The Drug Discovery segment focuses on building a portfolio of preclinical and clinical programs, internally and through collaborations. The company serves biopharmaceutical and industrial companies, academic institutions, and government laboratories worldwide. Schrödinger, Inc. was incorporated in 1990 and is based in New York, New York.
Sanofi logo

Sanofi

NASDAQ:SNY
Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products. In addition, it offers poliomyelitis, pertussis, and hib pediatric vaccines; influenza, booster, meningitis, and travel and endemic vaccines, which includes hepatitis A, typhoid, cholera, yellow fever, and rabies vaccines. The company also provides cough, cold, and flu, allergy, and pain care products, as well as physical, mental, and digestive wellness products; and offers products for itching, hydration, aging, cracking, overnight, and specialty skincare needs like eczema. Further, it has a collaboration and license agreement with Exscientia to develop up to 15 novel small-molecule for oncology and immunology; ABL Bio, Inc. to develop ABL301, a treatment for alpha-synucleinopathies; Blackstone Life Sciences to develop pivotal studies and clinical development program; and Seagen Inc. to design, develop, and commercialize antibody-drug conjugates for cancer. Additionally, the company has a collaboration agreement with IGM Biosciences, Inc. to develop, manufacture, and commercialize IgM antibody; Skyhawk Therapeutics, Inc to discover and develop novel small molecules; and Adagene Inc., for the discovery and development of antibody-based therapies. It also has collaborations with Scribe Therapeutics Inc. to develop genome editing technologies; and co-promotion service agreement with Provention Bio, Inc. for the commercialization of teplizumab. The company was formerly known as Sanofi-Aventis and changed its name to Sanofi in May 2011. Sanofi was incorporated in 1994 and is headquartered in Paris, France.
Sanofi logo

Sanofi

OTCMKTS:SNYNF
Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products. In addition, it offers poliomyelitis, pertussis, and hib pediatric vaccines; influenza, booster, meningitis, and travel and endemic vaccines, which includes hepatitis A, typhoid, cholera, yellow fever, and rabies vaccines. The company also provides cough, cold, and flu, allergy, and pain care products, as well as physical, mental, and digestive wellness products; and offers products for itching, hydration, aging, cracking, overnight, and specialty skincare needs like eczema. Further, it has a collaboration and license agreement with Exscientia to develop up to 15 novel small-molecule for oncology and immunology; ABL Bio, Inc. to develop ABL301, a treatment for alpha-synucleinopathies; Blackstone Life Sciences to develop pivotal studies and clinical development program; and Seagen Inc. to design, develop, and commercialize antibody-drug conjugates for cancer. Additionally, the company has a collaboration agreement with IGM Biosciences, Inc. to develop, manufacture, and commercialize IgM antibody; Skyhawk Therapeutics, Inc to discover and develop novel small molecules; and Adagene Inc., for the discovery and development of antibody-based therapies. It also has collaborations with Scribe Therapeutics Inc. to develop genome editing technologies; and co-promotion service agreement with Provention Bio, Inc. for the commercialization of teplizumab. The company was formerly known as Sanofi-Aventis and changed its name to Sanofi in May 2011. Sanofi was incorporated in 1994 and is headquartered in Paris, France.